App-Quantinova.ai

Sustained and durable response up to 24 weeks after last dose observed in a Phase 2a study (NCT03754309) of Amlitelimab (KY1005, SAR445229) a novel non-depleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe Atopic Dermatitis (AD)

Stephan Weidinger - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

KY1005

Family Impact of Moderate-to-Severe Atopic Dermatitis in Children Aged <12 years: Results From 732 Patients in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) Observational Study

Marjolein de Bruin-Weller - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Steven R. Feldman - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

bimekizumab

Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

Bruce Strober - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

bimekizumab

Long-Term Efficacy of Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis (AD): Results From an Open-Label Extension (OLE) Trial up to 4 years

Jacob P. Thyssen - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Sustained Long-Term Dupilumab Efficacy in Adult Patients With Moderate-to-Severe Atopic Dermatitis Transitioning From Weekly Dosing to Every Other Week: Results From an Open-Label Extension Trial

Lisa A. Beck - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

What a Headache: Erenumab Provoked Urticarial Drug Eruption

Michael Fong - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

Hydroxyzine

Atopic Dermatitis Treatment Patterns and Patient Burden in Russia and Poland

Erman GÃ¼ler - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis Who Had Inadequate Responses to Apremilast at Week 24 in the Phase 3 POETYK PSO-1 and PSO-2 Trials

April W Armstrong - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Apremilast

Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients With Moderate to Severe Psoriasis: Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Matthias Augustin - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Apremilast

Real-world safety and one-year effectiveness of dupilumab in Japanese patients with atopic dermatitis: an interim analysis of ongoing regulatory post-marketing surveillance

Hiroyuki Fujita - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

A multi-center, double-blind, randomized, placebo-controlled, Phase IIb dose-finding study to evaluate efficacy and safety of spesolimab in patients with moderate-to-severe palmoplantar pustulosis

A. David Burden - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Psoriasis 14, pustular

Interleukin

Dupilumab treatment restores skin barrier function and improves clinical and patient reported outcomes in adults and adolescents with moderate to severe atopic dermatitis

Robert Bissonnette - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Influence of GLP-1 analogue, liraglutide on MRI volume and cognition in patients with Alzheimer’s disease (Analysis from ELAD Study)

Paul Edison - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

Liraglutide

Validation of technology to monitor sleep and bed occupancy in older men and women

KIRAN KUMAR GURUSWAMY RAVINDRAN - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

Epoch

Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimer’s disease in the UK

Ashvini Keshavan - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Alzheimer's disease

18F-florbetapir

Does [18F]FDG and [18F]AV1451 PET predict neurodegeneration?

Megan Young - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

AV-1451

Influence of amyloid deposition on the interaction between tau and glucose metabolism

Joseph Nowell - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

AV-1451

CAIDE dementia risk score and progression of cerebral small vessel disease in cognitively healthy midlife adults: the PREVENT-Dementia study

Audrey Low - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cerebral small vessel disease

Fibrinogen (IV)

Diet and APOE as moderators of the relationship between trimethylamine N-oxide and biomarkers of Alzheimer's disease and glial activation

John C. Thorstenson - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

Carnitine

Filters

45280 Abstracts